| 摘要 |
A pharmaceutical composition comprises partial glycine agonist in a controlled release formulation for once a day administration to subjects with Parkinson's disease. The composition includes a controlled release material comprising a partial glycine agonist, a sustained release component, and at least one pharmaceutically acceptable excipient, wherein the composition upon initial administration of one dose provides a mean plasma concentration of the partial glycine agonist of at least 10 µg/mL and not more than 30 µg/mL within one hour of administration and continues to provide a mean plasma concentration of the partial glycine agonist of not more than 30 µg/mL for 12 - 16 hours. The partial glycine agonist is administered in a dose effective to enhance the efficacy of the levodopa or to reduce the frequency or severity of side effects of the levodopa. A method for treating Parkinson's disease in a subject comprises administering levodopa to the patient at least once per day and administering to the patient a once daily composition including a partial glycine agonist, formulated to provide a release profile wherein sufficient partial glycine agonist is delivered to the brain of the subject to enhance efficiency or reduce the side effects of each levodopa dose for up to 16 hours after administration of the partial glycine agonist.
|
